Literature DB >> 2931842

The effectiveness of Nissen fundoplication in neurologically impaired children with gastroesophageal reflux.

D W Vane, R P Harmel, D R King, E T Boles.   

Abstract

Fifty-seven of 101 Nissen fundoplications during the 4-year period, July 1979 to July 1983, were performed on neurologically impaired children. Mean age at the time of surgery was 5.9 years (range 1 month to 22 years). Indications for operation included: persistent vomiting, 57 patients (100%); failure to thrive, 49 patients (86%); repeated episodes of pneumonia, 49 patients (86%); esophagitis, 18 patients (32%); hiatal hernia, 14 patients (25%); episodes of apnea, 10 patients (18%); and esophageal stricture, six patients (10%). Forty-six of the 57 patients had previously failed a standard trial of nonsurgical management. Gastroesophageal reflux was documented by barium esophagograms in 51/56 patients (91%), chalasia scans in 28/32 patients (88%), esophagitis or stricture at endoscopy in 21/23 patients (91%), and acid reflux on pH monitoring in 13/16 patients (80%). Operative management included gastrostomy in 55 of the 57 patients and this was permanent in 50. Gastrostomies had previously been performed in nine patients but had failed to provide a reliable method of enteral feeding because of chronic reflux and aspiration. The surgical complication rate was 12%. Intraoperative esophageal perforation occurred in two patients, splenic tear in one, hepatic vein laceration in one, and a tight wrap in one. After surgery, bowel obstruction from adhesions developed in one patient and a midgut volvulus in another. Five of the children have died, none from causes related to the surgical procedure. Clinical and radiologic follow-up evaluations of all survivors have been done, with a mean follow-up of 3 years. In four patients the repair was felt to be inadequate. One patient had an esophageal stricture and three had recurring episodes of pneumonia. Three children showed radiologic evidence of persistent reflux, but only two were symptomatic. Two patients required a second antireflux procedure for reflux and are now free of symptoms. Nissen fundoplication appears to be a safe and beneficial procedure in neurological impaired children. Long-term follow-up evaluation of these patients showed satisfactory growth as well as a significant decrease in pulmonary disease associated with aspiration.

Entities:  

Mesh:

Year:  1985        PMID: 2931842

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Hospital variation in rates of concurrent fundoplication during gastrostomy enteral access procedures.

Authors:  Anne M Stey; Charles D Vinocur; R Lawrence Moss; Bruce L Hall; Mark E Cohen; Kari Kraemer; Clifford Y Ko; Brian D Kenney; Loren Berman
Journal:  Surg Endosc       Date:  2018-02-05       Impact factor: 4.584

2.  Boix-Ochoa (Partial Fundoplication) Treats Reflux, Even in Neurologically Impaired Patients. Can it Take the Title of "Gold Standard" from Total Fundoplication?

Authors:  Hasan Özkan Gezer; Semire Serin Ezer; Abdulkerim Temiz; Emine İnce; Akgün Hiçsönmez
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

3.  The non-refluxing gastrostomy: an evaluation.

Authors:  A Bianchi; B Pearse
Journal:  Pediatr Surg Int       Date:  1997-09       Impact factor: 1.827

4.  Operation for gastro-oesophageal reflux associated with severe mental retardation.

Authors:  L Spitz; K Roth; E M Kiely; R J Brereton; D P Drake; P J Milla
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

5.  Esophagogastric disconnection following failed fundoplication for the treatment of gastroesophageal reflux disease (GERD) in children with severe neurological impairment.

Authors:  Silvia Buratti; Rose Kamenwa; Ranjan Dohil; David Collins; Joel E Lavine
Journal:  Pediatr Surg Int       Date:  2004-10       Impact factor: 1.827

6.  Oral dysfunction following Nissen fundoplication.

Authors:  S M Borowitz; K C Borowitz
Journal:  Dysphagia       Date:  1992       Impact factor: 3.438

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.